AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6493883 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received information on burn prevention, including hot water heater settings and smoke detectors.
Number of subjects: 58
Study 6493883 — intervention group
Group type: COMPARATOR
Intervention: Control group received information on nutrition, dental care, safety in the car and home, child development, child rearing, illness management, and immunizations.
Number of subjects: 58
Study 6493883 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group regarding operational smoke detectors.
Number of subjects: 58
Study 6493883 — intervention group
Group type: COMPARATOR
Intervention: Control group regarding operational smoke detectors.
Number of subjects: 58
Study 31525928 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodissociation at 210 nm
Number of subjects: 2
Study 31525928 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodissociation at 201 nm
Number of subjects: 2
Study 29443767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 0.5 mg/kg + flurbiprofen axetil 150 mg
Number of subjects: 90
Study 29443767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 0.75 mg/kg + flurbiprofen axetil 150 mg
Number of subjects: 90
Study 29443767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 1.0 mg/kg + flurbiprofen axetil 150 mg
Number of subjects: 90
Study 29443767 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 26714442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 mcg/kg (Group L)
Number of subjects: 150
Study 26714442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 mcg/kg (Group H)
Number of subjects: 150
Study 26714442 — intervention group
Group type: COMPARATOR
Intervention: Second oral dose chloral hydrate 25 mg/kg (Group C)
Number of subjects: 150
Study 25146587 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support package (information booklet and trained physiotherapists)
Number of subjects: 148
Study 25146587 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control arm)
Number of subjects: 148
Study 22983273 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling (RMUS)
Number of subjects: 597
Study 22983273 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling (TMUS)
Number of subjects: 597
Study 20409302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 536
Study 20409302 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 536
Study 18707985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bolus dose tirofiban (n=491)
Number of subjects: 984
Study 18707985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=493)
Number of subjects: 984
Study 16372826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600mg administered orally
Number of subjects: 27
Study 12791229 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggul (Commiphora mukul)
Number of subjects: 25
Study 12791229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek (Trigonella foenum-graecum)
Number of subjects: 25
Study 12791229 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice
Number of subjects: 25
Study 12791229 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke (Cynara scolymus)
Number of subjects: 25
Study 10594798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine plus low-dose prednisone
Number of subjects: 49
Study 10594798 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 49
Study 9592327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive infection with MSOF
Number of subjects: 68
Study 9592327 — intervention group
Group type: COMPARATOR
Intervention: MSOF not combined with DIC
Number of subjects: 68
Study 9592327 — intervention group
Group type: COMPARATOR
Intervention: MSOF combined with DIC
Number of subjects: 68
Study 1649720 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (days 18-26)
Number of subjects: 11
Study 1649720 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase (days 2-8)
Number of subjects: 11
Study 1649720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phases
Number of subjects: 11
Study 3935120 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg)
Number of subjects: 11
Study 3935120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (250 mg)
Number of subjects: 11
Study 3935120 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (2.5-10 mg daily)
Number of subjects: 11
Study 3935120 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (125-500 mg daily)
Number of subjects: 11
Study 31473979 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 38
Study 31473979 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 38
Study 29590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live (ZV)
Number of subjects: 395
Study 29590326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 26110349 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Alanine (BA) supplementation (800 mg + 8 g dextrose)
Number of subjects: 22
Study 26110349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (8 g dextrose)
Number of subjects: 22
Study 26110349 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Alanine (BA) supplementation
Number of subjects: 22
Study 26110349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 22
Study 24650125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (dexamethasone, gabapentin, ibuprofen, paracetamol)
Number of subjects: 180
Study 24650125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 180
Study 24650125 — intervention group
Group type: COMPARATOR
Intervention: Traditional morphine and paracetamol regimen
Number of subjects: 180
Study 22288671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dipyrone 600 mg, isometheptene 60 mg, caffeine 60 mg)
Number of subjects: 84
Study 22288671 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg
Number of subjects: 84
Study 22288671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 22288671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 84
Study 22288671 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 84
Study 20437207 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (PHSO diet)
Number of subjects: 41
Study 20437207 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm stearin (PST diet)
Number of subjects: 41
Study 23111655 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 21
Study 23111655 — intervention group
Group type: COMPARATOR
Intervention: Control (empty gap)
Number of subjects: 21
Study 15818745 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 67
Study 15818745 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 67
Study 15818745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PTN)
Number of subjects: 67
Study 15818745 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine associated with GTN
Number of subjects: 67
Study 15818745 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine associated with ISDN
Number of subjects: 67
Study 15818745 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine associated with PTN
Number of subjects: 67
Study 12421266 — intervention group
Group type: COMPARATOR
Intervention: Schedule A: one dose at 0, 1, and 6 months
Number of subjects: 40
Study 12421266 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B: one dose at 0, 10, and 21 days
Number of subjects: 40
Study 9658362 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT)
Number of subjects: 20
Study 9658362 — intervention group
Group type: COMPARATOR
Intervention: Mimic therapeutic touch (mimic TT)
Number of subjects: 20
Study 7865912 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal RATS (n = 26)
Number of subjects: 55
Study 7865912 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal OKT3 (n = 29)
Number of subjects: 55
Study 2593767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) administered intravenously
Number of subjects: 8
Study 2593767 — intervention group
Group type: COMPARATOR
Intervention: Saline administered intravenously
Number of subjects: 8
Study 29695772 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring device for daily salt intake
Number of subjects: 158
Study 29695772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-monitoring device)
Number of subjects: 158
Study 28545917 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB patients receiving oral antibiotics
Number of subjects: 186
Study 28545917 — intervention group
Group type: COMPARATOR
Intervention: Controls receiving oral antibiotics
Number of subjects: 186
Study 28545917 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB patients receiving fluoroquinolones or sulfonamides
Number of subjects: 186
Study 25081390 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 ISCOMATRIX followed by recombinant fowlpox virus encoding full length NY‐ESO‐1 (rF‐NY‐ESO‐1)
Number of subjects: 39
Study 25081390 — intervention group
Group type: COMPARATOR
Intervention: NY‐ESO‐1 ISCOMATRIX alone
Number of subjects: 39
Study 24091318 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fortification (3 g/kg/d)
Number of subjects: 0
Study 24091318 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fortification (3.3 g/kg/d)
Number of subjects: 0
Study 24091318 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fortification (3.6 g/kg/d)
Number of subjects: 0
Study 21962415 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach to Goal (TTG) educational and behavioral support program with 5 to 8 telephone counseling sessions over 1 month
Number of subjects: 605
Study 21962415 — intervention group
Group type: COMPARATOR
Intervention: Brief Educational Intervention (BEI) - 1 hour educational intervention
Number of subjects: 605
Study 18248158 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser therapy (LLLT)
Number of subjects: 20
Study 18248158 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 20
Study 17361591 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (PT) for 48±6.4 months at 70% of maximal heart rate
Number of subjects: 230
Study 17361591 — intervention group
Group type: COMPARATOR
Intervention: Control group without physical training
Number of subjects: 230
Study 12728782 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions for family caregiving of elders
Number of subjects: 0
Study 12728782 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions for childhood chronic illness
Number of subjects: 0
Study 12728782 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions for spouse involvement in chronic adult illnesses
Number of subjects: 0
Study 12728782 — intervention group
Group type: EXPERIMENTAL
Intervention: Family interventions for health promotion/disease prevention
Number of subjects: 0
Study 11012498 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 25 microg
Number of subjects: 60
Study 11012498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg and ropivacaine 2.5 mg
Number of subjects: 60
Study 11012498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 microg and bupivacaine 2.5 mg
Number of subjects: 60
Study 8994314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (3 doses of 1 ml each, containing at least 720 ELISA Units of HAV antigen and 20 micrograms of recombinant HBsAg, administered at 0, 1, and 6 months)
Number of subjects: 150
Study 8994314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine
Number of subjects: 150
Study 1427652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha alone (5 million units/m2 three times per week)
Number of subjects: 45
Study 1427652 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with lymphoblastoid interferon-alpha and levamisole (150 mg three times per week)
Number of subjects: 45
Study 1427652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha alone
Number of subjects: 45
Study 1427652 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with lymphoblastoid interferon-alpha and levamisole
Number of subjects: 45
Study 3880877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel administered intracervically
Number of subjects: 103
Study 3880877 — intervention group
Group type: COMPARATOR
Intervention: Demoxytocin buccal tablets
Number of subjects: 103
Study 31135822 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated approval drugs pending confirmatory data
Number of subjects: 85
Study 31135822 — intervention group
Group type: COMPARATOR
Intervention: Drugs with regular approval
Number of subjects: 85
Study 31135822 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate (RR)
Number of subjects: 85
Study 31135822 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response rate
Number of subjects: 85
Study 30942962 — intervention group
Group type: COMPARATOR
Intervention: 67% w/w NaHCO3 toothpaste
Number of subjects: 56
Study 30942962 — intervention group
Group type: COMPARATOR
Intervention: 0% w/w NaHCO3 toothpaste
Number of subjects: 56
Study 30942962 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% w/w NaHCO3 toothpaste
Number of subjects: 56
Study 30942962 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% w/w NaHCO3 toothpaste
Number of subjects: 56
Study 30942962 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% w/w NaHCO3 toothpaste
Number of subjects: 56
Study 26675187 — intervention group
Group type: EXPERIMENTAL
Intervention: Academy coaching intervention
Number of subjects: 121
Study 26675187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 25461793 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related cognitive-behavioral therapy (WCBT) plus vocational services as usual (VSAU)
Number of subjects: 58
Study 25461793 — intervention group
Group type: COMPARATOR
Intervention: Vocational services as usual (VSAU)
Number of subjects: 58
Study 25461793 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related cognitive-behavioral therapy (WCBT)
Number of subjects: 58
Study 22427021 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes (Quest© brand)
Number of subjects: 67
Study 22427021 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate nicotine content cigarettes
Number of subjects: 67
Study 21034483 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care pathway involving exercise, massage, acupuncture, and cognitive behavioral therapy.
Number of subjects: 0
Study 18981506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic filters
Number of subjects: 115
Study 18981506 — intervention group
Group type: COMPARATOR
Intervention: Control (no ceramic filters)
Number of subjects: 115
Study 15803929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 15803929 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0
Study 15803929 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVCY)
Number of subjects: 0
Study 15803929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose IVCY induction followed by AZA maintenance
Number of subjects: 0
Study 15803929 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose IVCY induction followed by AZA maintenance
Number of subjects: 0
Study 15803929 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral CY induction followed by AZA maintenance
Number of subjects: 0
Study 12160098 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.62 g/kg)
Number of subjects: 48
Study 12160098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12160098 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement (reward for performance)
Number of subjects: 48
Study 10212739 — intervention group
Group type: EXPERIMENTAL
Intervention: New Religious Movements (NRMs)
Number of subjects: 0
Study 10212739 — intervention group
Group type: EXPERIMENTAL
Intervention: Deluded psychotic in-patients
Number of subjects: 0
Study 10212739 — intervention group
Group type: COMPARATOR
Intervention: Control groups (non-religious and Christian)
Number of subjects: 0
Study 8682918 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with endodontic infection
Number of subjects: 133
Study 8682918 — intervention group
Group type: COMPARATOR
Intervention: Teeth without endodontic infection or subsiding endodontic involvement
Number of subjects: 133
Study 2223892 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced respiration (10 minutes of slow-breathing training)
Number of subjects: 36
Study 2223892 — intervention group
Group type: COMPARATOR
Intervention: Attention control (counting pacing tones)
Number of subjects: 36
Study 667244 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (10 mg and 20 mg)
Number of subjects: 24
Study 667244 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg and 300 mg)
Number of subjects: 24
Study 667244 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 'no-drug' treatment
Number of subjects: 24
Study 667244 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise condition
Number of subjects: 24
Study 31845065 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat
Number of subjects: 0
Study 31845065 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 31093801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program for anxiety and social deficits
Number of subjects: 40
Study 31093801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 27494342 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture with physiotherapy tape
Number of subjects: 61
Study 27494342 — intervention group
Group type: COMPARATOR
Intervention: Usual posture with physiotherapy tape
Number of subjects: 61
Study 26525008 — intervention group
Group type: EXPERIMENTAL
Intervention: Solobond M + Grandio
Number of subjects: 30
Study 26525008 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac + Tetric Ceram
Number of subjects: 30
Study 26525008 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar restorations
Number of subjects: 30
Study 26525008 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 30
Study 26158178 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia
Number of subjects: 71
Study 26158178 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 71
Study 23071718 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (CR)
Number of subjects: 40
Study 23071718 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study 18927148 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy with support from 'hospital in the home' (HiTH)
Number of subjects: 44
Study 18927148 — intervention group
Group type: COMPARATOR
Intervention: Traditional inpatient hospitalisation
Number of subjects: 44
Study 17888067 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 68
Study 17888067 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 68
Study 14999696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 13 to 15 mg/kg/d for 2 years
Number of subjects: 166
Study 14999696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 12111084 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 90
Study 12111084 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (3 times per week, starting with 10-min duration)
Number of subjects: 90
Study 12111084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 9260729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102) infused over 4 hours at doses of 15, 32, 50, or 73 microg/kg
Number of subjects: 20
Study 9260729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102) at total doses of 32 microg/kg
Number of subjects: 20
Study 9260729 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of Aptiganel hydrochloride (CNS 1102)
Number of subjects: 20
Study 9260729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102)
Number of subjects: 20
Study 9260729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel hydrochloride (CNS 1102) at total doses of up to 32 microg/kg infused over 4 hours
Number of subjects: 20
Study 8240471 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway
Number of subjects: 104
Study 8240471 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 104
Study 3481040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 1000 mg/m2 iv over 24 hours weekly for 3 weeks, then every 6 weeks for 72 weeks, combined with low-dose 6-mercaptopurine (6MP; 50 mg/m2 orally per day) and methotrexate (MTX; 25 mg/m2 orally per week)
Number of subjects: 108
Study 3481040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 108
Study 30770262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 424
Study 30770262 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 424